DBV Technologies will submit for approval of the peanut allergy patch in 2026. Image credit: Uncitaby / Shutterstock.com. DBV Technologies will be making another attempt at gaining US Food and Drug ...
The solution leverages AI to match molecular, demographic, and clinical history data against eligibility criteria from active trials. Credit: MUNGKHOOD STUDIO / Shutterstock.com. Anova Enterprises has ...
Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback